Skip to main content
Retour
Watch Compare

Barinthus Biotherapeutics plc.

Qualité des données : 100%
BRNS
Nasdaq Manufacturing Chemicals
0,57 €
▲ 0,02 € (3,09%)
Cap. Boursière: 22,47 M
Prix
0,55 €
Cap. Boursière
22,47 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -48,02 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-71,11%
En dessous de la moyenne du secteur (-53,41%)
ROIC-51,79%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio8,04
Interest Coverage-1383,43

Valorisation

PE (TTM)
-0,34
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,27
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,3 -1,5
P/B 0,3 1,6
ROE % -71,1 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -66,43 M
ROE -71,11% ROA -55,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -48,02 M
ROIC -51,79% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,04
Interest Coverage -1383,43 Asset Turnover 0,00
Working Capital 75,98 M Tangible Book Value 69,56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,34 Forward P/E N/A
P/B Ratio 0,27 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -213,72%
Market Cap 22,47 M Enterprise Value -51,81 M
Per Share
EPS (Diluted TTM) -1,64 Revenue / Share 0,00
FCF / Share -1,18 OCF / Share -1,17
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 72,28%
SBC-Adj. FCF -48,93 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 14,97 M 802 000,0 44,70 M 268 000,0
Net Income -66,43 M -61,07 M -73,35 M 5,34 M -50,87 M
EPS (Diluted) -1,64 -1,55 -1,91 0,14 -1,96
Gross Profit — — — — —
Operating Income -70,56 M -67,97 M -83,91 M -4,04 M -45,22 M
EBITDA — — — — —
R&D Expenses 25,56 M 42,24 M 44,87 M 42,35 M 20,37 M
SG&A Expenses — — — — —
D&A 5,85 M 5,80 M 5,43 M 4,32 M 602 000,0
Interest Expense 51 000,0 53 000,0 28 000,0 19 000,0 2,67 M
Income Tax -175 000,0 -44 000,0 -3,08 M -4,47 M -28 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 98,17 M 160,33 M 214,51 M 270,21 M 280,72 M
Total Liabilities 23,88 M 30,19 M 27,51 M 27,00 M 28,15 M
Shareholders' Equity 74,21 M 130,03 M 186,78 M 242,90 M 252,56 M
Total Debt — — — — —
Cash & Equivalents 70,46 M 110,66 M 142,09 M 194,39 M 214,05 M
Current Assets 77,79 M 125,74 M 156,91 M 213,04 M 226,77 M
Current Liabilities 10,02 M 15,66 M 12,60 M 12,24 M 11,16 M